Literature DB >> 1385320

GM-CSF and G-CSF stimulate the synthesis of histamine and putrescine in the hematopoietic organs in vivo.

Y Endo1, T Kikuchi, Y Takeda, Y Nitta, H Rikiishi, K Kumagai.   

Abstract

Histamine and putrescine (a precursor of polyamines) are formed by histidine decarboxylase (HDC) and ornithine decarboxylase (ODC), respectively. Within a few hours after injection of a lipopolysaccharide (LPS) into mice, HDC is induced in the liver, spleen, lung and bone marrow, and ODC is induced in the liver, spleen and bone marrow. Since LPS is known to stimulate the production of various cytokines, the abilities of various cytokines to induce HDC and ODC in the tissues of mice were examined. IL-2, IL-6, IL-8, IFN gamma and M-CSF were ineffective. IL-1 alpha, IL-1 beta, TNF alpha and TNF beta induced HDC and ODC, as does LPS. On the other hand, GM-CSF and G-CSF induced HDC and ODC only in the spleen and bone marrow within a few hours after their injection. These results suggest that, in addition to their roles in inflammation or immune responses, HDC and ODC are also involved in an early stage of hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385320     DOI: 10.1016/0165-2478(92)90086-4

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  12 in total

1.  Induction of histidine decarboxylase in skeletal muscle in mice by electrical stimulation, prolonged walking and interleukin-1.

Authors:  Y Endo; T Tabata; H Kuroda; T Tadano; K Matsushima; M Watanabe
Journal:  J Physiol       Date:  1998-06-01       Impact factor: 5.182

2.  Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice.

Authors:  M Nakamura; T Ando; M Abe; K Kumagai; Y Endo
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  Enhancement by galactosamine of lipopolysaccharide(LPS)-induced tumour necrosis factor production and lethality: its suppression by LPS pretreatment.

Authors:  Y Endo; M Shibazaki; K Yamaguchi; K Kai; S Sugawara; H Takada; H Kikuchi; K Kumagai
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

4.  Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate.

Authors:  Y Endo; M Shibazaki; K Yamaguchi; M Nakamura; H Kosugi
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

5.  Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.

Authors:  K Yamaguchi; K Motegi; Y Iwakura; Y Endo
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

6.  Histidine decarboxylase deficiency inhibits NBP-induced extramedullary hematopoiesis by modifying bone marrow and spleen microenvironments.

Authors:  Hirotada Otsuka; Yasuo Endo; Hiroshi Ohtsu; Satoshi Inoue; Syunya Noguchi; Masanori Nakamura; Satoshi Soeta
Journal:  Int J Hematol       Date:  2021-01-04       Impact factor: 2.490

7.  Experimental evidence for structure-activity features in common between mammalian histidine decarboxylase and ornithine decarboxylase.

Authors:  N Engel; M T Olmo; C S Coleman; M A Medina; A E Pegg; F Sánchez-Jiménez
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

8.  Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo.

Authors:  Y Endo; M Nakamura; T Kikuchi; H Shinoda; Y Takeda; Y Nitta; K Kumagai
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

9.  Increase in histamine production by inflammatory exudate in the chronic phase of allergic inflammation in rats.

Authors:  N Hirasawa; M Shiraishi; S Oikawa; S Mue; K Ohuchi
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

10.  Effects of macrophage depletion on the induction of histidine decarboxylase by lipopolysaccharide, interleukin 1 and tumour necrosis factor.

Authors:  Y Endo; M Nakamura; Y Nitta; K Kumagai
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.